|

Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies

RECRUITINGPhase 2Sponsored by Shanghai Jiao Tong University School of Medicine
Actively Recruiting
PhasePhase 2
SponsorShanghai Jiao Tong University School of Medicine
Started2022-06-01
Est. completion2025-06-01
Eligibility
Age55 Years – 65 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05436561

Summary

In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML \>=55 years.

Eligibility

Age: 55 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age 55-65
* patients with HLA-matched sibling donors, 9-10/10 matched unrelated donors or haplo-identical donors.
* patients with AML in remission, or MDS in any stage, or CMML in any stage
* inform consent provided

Exclusion Criteria:

* patients with abnormal liver (\>3N), renal (1.5N) or cardiac function
* patients with active infection

Conditions2

CancerDisease Free Survival

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.